American Heart Journal
Volume 157, Issue 1 , Pages 125-131, January 2009

The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial

  • Harvey D. White, MB, ChB, DSc

      Affiliations

    • Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    • Corresponding Author InformationReprint requests: Harvey White, DSc, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, 1030 Auckland, New Zealand.
    • ,
  • Richard Gallo, MD

      Affiliations

    • Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
    • ,
  • Marc Cohen, MD

      Affiliations

    • Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ
    • ,
  • Ph. Gabriel Steg, MD

      Affiliations

    • Service de Cardiologie, Hôpital Bichat, Paris, France
    • ,
  • Philip E. Aylward, MB, ChB, PhD

      Affiliations

    • Department of Cardiology, Flinders Medical Center, Adelaide, South Australia, Australia
    • ,
  • Christoph Bode, MD, PhD

      Affiliations

    • Abteilung Innere Medizin III, Universitätsklinikum Freiburg, Freiburg, Germany
    • ,
  • Steve Steinhubl, MD

      Affiliations

    • The Adjunct Faculty, Geisinger Clinic, Geisinger Center for Health Research, Danville, PA
    • ,
  • Gilles Montalescot, MD, PhD

      Affiliations

    • Institut de Cardiologie (AP-HP) and INSERM Unit #856 Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

Received 15 May 2008; accepted 20 August 2008. published online 13 November 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Registered trial no. NCT00077844.

 The STEEPLE trial was funded by Sanofi Aventis (Paris, France). Dr White reports receiving grant support, consulting fees, and lecture fees from Sanofi Aventis and The Medicines Company (Parsippany, NJ), and grant support from Proctor and Gamble (Cincinnati, OH), Alexion (Cheshire, CT), Schering Plough (Kenilworth, NJ), and Eli Lilly (Indianapolis, IN). Dr Gallo reports having received grant support, consulting fees, and lecture fees from Sanofi Aventis; lecture fees from Abbott Interventional (Chicago, IL), Oryx Pharmaceuticals (Mississauga, Ontario, Canada), and Biovail Pharmaceuticals (Mississauga, Ontario, Canada); and consulting fees from Biovail Pharmaceuticals. Dr Cohen reports receiving grant support from Aventis Pharmaceuticals (Strasbourg, France), consulting fees from Sanofi Aventis and AstraZeneca (London, United Kingdom), and lecture fees from Sanofi Aventis, Merck (Whitehouse Station, NJ), and Schering (Berlin-Wedding, Germany). Dr Steg reports receiving grant support from Sanofi Aventis; consulting fees from Sanofi-Aventis, Takeda (Osaka, Japan), AstraZeneca, Bristol-Myers Squibb (New York, NY), Endotis (Romainville, France), Lilly, Merck Sharpe & Dohme (Whitehouse Station, NJ), GlaxoSmithKline (London, United Kingdom), Pfizer (New York, NY), Servier (Neuilly-sur-Seine, France), The Medicines Company; and speakers bureau from AstraZeneca, Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharpe & Dohme, Novartis (Basel, Switzerland), Nycomed (Zurich, Switzerland), Sanofi Aventis, Sankyo (Tokyo, Japan), Servier, The Medicines Company, and ZLB Behring (West Sussex, United Kingdom). Dr Aylward reports receiving grant support from Sanofi Aventis, Proctor and Gamble, Alexion, The Medicines Company, Schering Plough, and Eli Lilly, as well as consulting fees and lecture fees from Sanofi Aventis and Bristol-Myers Squibb. Dr Bode reports receiving consulting and lecture fees from Sanofi Aventis, Lilly, and GlaxoSmithKline; consulting fees from Nycomed; and lecture fees from AstraZeneca. Dr Steinhubl is currently employed by The Medicines Company; before this appointment, Dr Steinhubl reports receiving consulting fees from Sanofi-Aventis, The Medicines Company, AstraZeneca, Eli Lilly, Cardax Pharmaceuticals (Aiea, HI), and Daiichi Sankyo. Dr Montalescot reports receiving grant support, consulting fees, and lecture fees from Sanofi Aventis, Eli Lilly, and Bristol-Myers Squibb; consulting and lecture fees from Schering-Plough and The Medicines Company; and lecture fees from GlaxoSmithKline.

PII: S0002-8703(08)00734-5

doi:10.1016/j.ahj.2008.08.019

American Heart Journal
Volume 157, Issue 1 , Pages 125-131, January 2009

Article Tools

* Image Usage & Resolution